| HOME >> MEDICINE >> TECHNOLOGY |
25,7633,86278,42513,942 Selling, general and administrative
61,37736,384223,882108,936 Research and development
7,2773,76420,47714,120 Intangible asset amortization
21,9071,86265,3517,448 Total operating expenses
116,32445,872388,135144,446 Income from operations
67,37937,664197,844127,831 Interest expense, net
(7,670)(41)(16,869)(1,600) Foreign currency loss
(2,263)-(3,620)- Loss on extinguishment of debt
-(150)-(1,247) Income from continuing operations before income tax benefit
57,44637,473177,355124,984 Income tax benefit
(108,760)-(83,794)- Income from continuing operations
166,20637,473261,149124,984 Income from discontinued operations, net of tax
34,345-27,437- Net income$ 200,551$ 37,473$ 288,586$ 124,984Basic income per ordinary share:Income from continuing operations
$
2.87$
.88$
4.61$
3.01Income from discontinued operations
0.59-0.48-Net income
$
3.46$
.88$
5.09$
3.01Diluted income per ordinary share:Income from continuing operations
$
2.71$
.79$
4.34$
2.67Income from discontinued operations
0.57-0.45-Net income
$
3.28$
.79$
4.79$
2.67 Weighted-average ordinary shares used in per share computations: Basic
57,96842,36756,64341,499 Diluted
61,23447,45160,19546,798 JAZZ PHARMACEUTICALS PLC SUMMARY OF PRODUCT SALES, NET (In thousands) (Unaudited) Three Months EndedYear EndedDecember 31,December 31,2012201120122011Xyrem
$ 113,514$ 71,845$ 378,663$ 233,348Erwinaze/Erwinase (1)
34,423-72,083-Prialt (1)
5,8
'/>"/>
| SOURCE Jazz Pharmaceuticals plc Copyright©2012 PR Newswire. All rights reserved |